Fibroblast growth factor 21 inhibition aggravates cardiac dysfunction in diabetic cardiomyopathy by improving lipid accumulation

Diabetic cardiomyopathy (DCM) is one of the major causes of morbidity and mortality in diabetic patients. Recent studies have demonstrated an increased level of fibroblast growth factor 21 (FGF21) in the plasma of DCM patients, and FGF21 has been proven to be a cardiovascular protector of the heart....

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Cui, Meng, Zheying, Zheng, Yuanyi, Hu, Bing, Shen, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763648/
https://www.ncbi.nlm.nih.gov/pubmed/29375676
http://dx.doi.org/10.3892/etm.2017.5375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763648/
https://www.ncbi.nlm.nih.gov/pubmed/29375676
http://dx.doi.org/10.3892/etm.2017.5375

Ejemplares similares